BACKGROUND The increased use of antidepressant treatment during pregnancy occurred without firm evidence on safety/efficacy. The present study investigated the correlation among S100B and paroxetine blood levels with the occurrence of short-term post-natal neurological abnormalities. METHODS We conducted a cross-sectional study in 50 pregnant women using paroxetine because of depression and in 150 controls. Standard laboratory parameters and S100B were measured at seven monitoring time-points (maternal blood: T1, 16-20 wks; T2, 27-30 wks; T3, 35-40 wks; T4, at delivery; amniotic fluid, T5; venous and arterial cord blood, T6-T7). Paroxetine levels were measured at T1-T6. Neurological outcome was set at 7th day from birth. RESULTS Higher S100B concentrations at T1-T7 were found in the paroxetine-treated group. S100B correlated with paroxetine blood levels. The paroxetine/S100B ratio cut-off of 1.31 at T2 achieved sensitivity 100%, specificity 96.5% and positive/negative predictive values 87.5-100, respectively, as a single marker to predict adverse neonatal neurological outcome. CONCLUSIONS The present study offers additional support to the usefulness of longitudinal S100B and drug level monitoring in depressed pregnant women and in the early detection of cases at risk for short-term neurological abnormalities. Results open the way at further investigations correlating antidepressant drugs and neurobiomarkers in the maternal bloodstream.

中文翻译：

---

产前孕妇抗抑郁药治疗以剂量依赖方式影响母胎生物液中的S100B水平。

背景技术在怀孕期间抗抑郁治疗的增加使用没有安全性/有效性的确凿证据。本研究调查了S100B和帕罗西汀血药浓度与短期产后神经系统异常的发生之间的相关性。方法我们对50名因抑郁而使用帕罗西汀的孕妇和150名对照进行了横断面研究。在七个监测时间点测量标准实验室参数和S100B（母体血：T1，16-20 wks; T2，27-30 wks; T3，35-40 wks;产时T4;羊水T5;静脉血和动脉血，T6-T7）。在T1-T6时测量帕罗西汀水平。神经学结果设定为出生后第7天。结果在帕罗西汀治疗组中，T1-T7的S100B浓度较高。S100B与帕罗西汀血药浓度相关。帕罗西汀/ S100B比值在T2时的截断值为1.31，分别作为预测新生儿神经系统不良结局的单一标志物达到100％的敏感性，96.5％的特异性和87.5-100的阳性/阴性预测值。结论本研究为纵向S100B和药物水平监测在抑郁症孕妇以及早期发现有短期神经系统异常风险的病例中的有效性提供了额外的支持。结果为进一步研究母血中的抗抑郁药和神经生物标志物开辟了道路。作为预测新生儿神经系统不良后果的单一标记。结论本研究为纵向S100B和药物水平监测在抑郁症孕妇以及早期发现有短期神经系统异常风险的病例中的有效性提供了额外的支持。研究结果为进一步研究孕妇血液中的抗抑郁药和神经生物标志物开辟了道路。作为预测新生儿神经系统不良后果的单一标记。结论本研究为纵向S100B和药物水平监测在抑郁症孕妇以及早期发现有短期神经系统异常风险的病例中的有效性提供了额外的支持。结果为进一步研究母血中的抗抑郁药和神经生物标志物开辟了道路。